TransMedics (TMDX) Cash from Financing Activities (2018 - 2026)

TransMedics has reported Cash from Financing Activities for 9 years, with the latest figure at $3.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 24.24% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at $17.6 million (down 22.56% YoY), and the FY2025 full-year result was $16.9 million, down 26.3% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $3.8 million, up from $3.1 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $394.0 million in Q2 2023, with the low at $237000.0 in Q2 2022.
• Average Cash from Financing Activities over 5 years is $36.0 million, with a median of $3.2 million recorded in 2024.
• Peak annual rise in Cash from Financing Activities reached 166150.21% in 2023, while the deepest fall reached 99.07% in 2023.
• Tracing TMDX's Cash from Financing Activities over 5 years: stood at $3.1 million in 2022, then tumbled by 69.85% to $924000.0 in 2023, then gained by 28.35% to $1.2 million in 2024, then jumped by 161.3% to $3.1 million in 2025, then climbed by 21.39% to $3.8 million in 2026.
• The last three Cash from Financing Activities figures came in at $3.8 million (Q1 2026), $3.1 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.

Peer Comparison